Skip to main content

Alembic receives USFDA approval for Olmesartan Medoxomil Tablets and Olmesartan Medoxomil

 

Clinical courses

Alembic Pharmaceuticals Limited announced that the Company has received final approvals from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDAs) for Olmesartan Medoxomil Tablets, 5 mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5mg, 40/12.5mg and 40/25mg.

The approved ANDAs are therapeutically equivalent to the reference listed drug products (RLDs) Benicar Tablets 5mg, 20mg and 40mg and Benicar HOT® Tablets, 20/12.5mg, 40/12.5mg and 40/25mg, of Daiichi Sankyo Inc. Approved ANDAs are indicated for the treatment of hypertension.

Benicar and Benicar HOT have an estimated market size of US$ 1.8 billion for twelve months ending December 2016 according to IMS.

 

Alembic now has a total of 55 ANDA approvals (49 final approvals and 6 tentative approvals) from the USFDA.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email